Insider Selling: Adicet Bio, Inc. (NASDAQ:ACET) Insider Sells 6,968 Shares of Stock

Adicet Bio, Inc. (NASDAQ:ACETGet Rating) insider Blake Aftab sold 6,968 shares of the stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $18.00, for a total transaction of $125,424.00. Following the transaction, the insider now owns 38,967 shares in the company, valued at $701,406. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Blake Aftab also recently made the following trade(s):

  • On Monday, August 1st, Blake Aftab sold 6,968 shares of Adicet Bio stock. The shares were sold at an average price of $16.64, for a total transaction of $115,947.52.
  • On Tuesday, July 5th, Blake Aftab sold 1,363 shares of Adicet Bio stock. The shares were sold at an average price of $14.50, for a total transaction of $19,763.50.

Adicet Bio Stock Up 2.7 %

Shares of ACET stock opened at $18.74 on Friday. The firm’s 50-day moving average is $14.64 and its two-hundred day moving average is $14.44. Adicet Bio, Inc. has a 12 month low of $6.25 and a 12 month high of $21.17.

Adicet Bio (NASDAQ:ACETGet Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.17. Adicet Bio had a negative net margin of 93.18% and a negative return on equity of 13.61%. The business had revenue of $24.99 million for the quarter, compared to the consensus estimate of $13.74 million. As a group, equities analysts predict that Adicet Bio, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

ACET has been the subject of several recent analyst reports. TheStreet downgraded shares of Adicet Bio from a “c-” rating to a “d+” rating in a research note on Wednesday, June 1st. JMP Securities restated a “buy” rating and issued a $21.00 target price on shares of Adicet Bio in a research note on Tuesday, June 7th. Finally, StockNews.com downgraded shares of Adicet Bio from a “hold” rating to a “sell” rating in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Adicet Bio has an average rating of “Moderate Buy” and an average target price of $29.29.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Adicet Bio by 69.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,672 shares of the company’s stock worth $33,000 after purchasing an additional 685 shares during the period. J. Goldman & Co LP raised its position in Adicet Bio by 4.7% during the 1st quarter. J. Goldman & Co LP now owns 19,650 shares of the company’s stock worth $392,000 after buying an additional 878 shares during the last quarter. American International Group Inc. raised its position in Adicet Bio by 15.1% during the 1st quarter. American International Group Inc. now owns 12,789 shares of the company’s stock worth $255,000 after buying an additional 1,675 shares during the last quarter. Amalgamated Bank purchased a new position in Adicet Bio during the 1st quarter worth $51,000. Finally, JPMorgan Chase & Co. raised its position in Adicet Bio by 18.1% during the 1st quarter. JPMorgan Chase & Co. now owns 16,766 shares of the company’s stock worth $335,000 after buying an additional 2,564 shares during the last quarter. Institutional investors and hedge funds own 76.21% of the company’s stock.

Adicet Bio Company Profile

(Get Rating)

Adicet Bio, Inc, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients.

Read More

Insider Buying and Selling by Quarter for Adicet Bio (NASDAQ:ACET)

Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.